search
Back to results

Amblyopia and Neurovascular Coupling in the Retina of Humans

Primary Purpose

Amblyopia, Regional Blood Flow

Status
Withdrawn
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Flicker
Retinal Vessel Diameter
Retinal Blood Flow
Sponsored by
Medical University of Vienna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Amblyopia focused on measuring Amblyopia, Retinal vessel diameters, Retinal blood flow, Flicker

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Inclusion criteria for healthy subjects: Women and men, aged between 18 and 60 years Matched with regard to age, sex and smoking status Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Normal ophthalmic findings, ametropia of less than 3.0 dpt Inclusion criteria for patients with amblyopia as a result of anisometropia or strabismus: Normal ophthalmic findings except amblyopia on one eye resulting from anisometropia or strabismus with a visual acuity between log Mar 0.3 and 0.7 (Snellen 0.2-0.5) with best correction on the amblyopic eye and 0.1 (Snellen 0.9) or better on the contralateral eye Anisometropia of more 3 dpt (patients with anisometropia) Women and men, aged between 18 and 60 years Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Exclusion Criteria: Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study pregnancy Treatment in the previous 3 weeks with any drug Symptoms of a clinically relevant illness in the 3 weeks before the first study day Blood donation during the previous 3 weeks

Sites / Locations

  • Department of Clinical Pharmacology

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Healthy Control Subjects

Subjects with amblyopia

Arm Description

Outcomes

Primary Outcome Measures

Retinal vessel diameter
Time course of diameter changes induced by flicker light stimulation

Secondary Outcome Measures

Full Information

First Posted
April 6, 2006
Last Updated
December 5, 2014
Sponsor
Medical University of Vienna
search

1. Study Identification

Unique Protocol Identification Number
NCT00312390
Brief Title
Amblyopia and Neurovascular Coupling in the Retina of Humans
Official Title
Amblyopia and Neurovascular Coupling in the Retina of Humans
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Withdrawn
Study Start Date
July 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Medical University of Vienna

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The visual disorder of amblyopia affects 2% to 3% of the population. Amblyopia is a developmental condition that is characterized by reduced vision of the eye due to the presence of a sensory impediment during visual development, such as strabismus (ocular misalignment) or anisometropia (unequal refractive error), occurring early in life. Recent studies in humans and animals point towards a cortical locus for the processing deficit in amblyopia, revealing sensory deficits at the signal cell level that include reduced spatial resolution, reduced contrast sensitivity, and a reduced number of binocular neural cells. In the retina, however, no abnormalities have yet been reported. Like in the brain blood flow in the retina is coupled to neuronal activity. This phenomenon has been measured by different study groups with non invasive techniques in the brain and retina. We therefore use a Zeiss fundus camera for the assessment of retinal vessel diameters. This so called retinal vessel analyzer (RVA) is a combination of a fundus camera connected to a high resolution video camera equipped with a software based analyzing system. An unprecedented reproducibility and sensitivity of retinal vessel diameter measurements is attained with this system. In addition this system allows real time analysis of retinal vessels as well as off-line determinations from video tape. A special provocation test, which minimizes risk and discomfort to the subject under study is applied through the illumination pathway of the fundus camera: Diffuse luminance flicker is used as a stimulus to augment intrinsic mechanisms by which the retina can vary the vascular supply, in correspondence with local variations of functional activity. This system allows to study the flicker response of retinal vessels, which is within a magnitude of 6 to 8%. However, the exact mechanisms underlying this phenomenon are not fully understood. Especially in the eye it is not clear whether it is an exclusive metabolic effect within the retina and the surrounding blood vessels or dependent of central regulatory brain functions. The purpose of the current study is to improve our understanding of the mechanisms underlying flicker evoked responses of retinal blood vessels in humans. It is not clear whether the retina of amblyopic eyes can regulate retinal blood flow in response to increased metabolic demands as induced during flicking light stimulation. A detail understanding of the metabolic and functional processes within the retina of patients with amblyopia is a prerequisite for further research to prevent amblyopia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amblyopia, Regional Blood Flow
Keywords
Amblyopia, Retinal vessel diameters, Retinal blood flow, Flicker

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy Control Subjects
Arm Type
Other
Arm Title
Subjects with amblyopia
Arm Type
Other
Intervention Type
Procedure
Intervention Name(s)
Flicker
Intervention Type
Procedure
Intervention Name(s)
Retinal Vessel Diameter
Intervention Type
Procedure
Intervention Name(s)
Retinal Blood Flow
Primary Outcome Measure Information:
Title
Retinal vessel diameter
Time Frame
10 minutes
Title
Time course of diameter changes induced by flicker light stimulation
Time Frame
10 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for healthy subjects: Women and men, aged between 18 and 60 years Matched with regard to age, sex and smoking status Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Normal ophthalmic findings, ametropia of less than 3.0 dpt Inclusion criteria for patients with amblyopia as a result of anisometropia or strabismus: Normal ophthalmic findings except amblyopia on one eye resulting from anisometropia or strabismus with a visual acuity between log Mar 0.3 and 0.7 (Snellen 0.2-0.5) with best correction on the amblyopic eye and 0.1 (Snellen 0.9) or better on the contralateral eye Anisometropia of more 3 dpt (patients with anisometropia) Women and men, aged between 18 and 60 years Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Exclusion Criteria: Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study pregnancy Treatment in the previous 3 weeks with any drug Symptoms of a clinically relevant illness in the 3 weeks before the first study day Blood donation during the previous 3 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gabriele Fuchsjaeger-Mayrl, MD
Organizational Affiliation
Department of Clinical Pharmacology, Medical University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Clinical Pharmacology
City
Vienna
ZIP/Postal Code
1090
Country
Austria

12. IPD Sharing Statement

Learn more about this trial

Amblyopia and Neurovascular Coupling in the Retina of Humans

We'll reach out to this number within 24 hrs